november AG

euro adhoc: november AG
Capital measures
Executive and supervisory board propose resolution of capital reduction and capital increase against contribution in kind for financial restructuring of the company to shareholder’s meeting The executive and

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- Company Information 04.04.2007 Erlangen, 04. April 2007. In order to continue the financial restructuring of november AG i.I., the annual shareholder’s meeting, taking place on May 22nd, 2007, shall decide on the capital reduction in a simplified procedure as compensation for losses and depreciations in assets from Euro 7,508,320.00 by Euro 3,754,160.00 to Euro 3,754,160.00 (at the rate of two to one). Furthermore, the shareholder’s meeting shall for the necessary financial restructuring decide on a capital increase against contribution in kind with the exclusion of the shareholders’ subscription rights in return for the contribution of the companies IBL Gesellschaft für Immunchemie und Immunbiologie mbH (IBL), Hamburg, and PROGEN Biotechnik GmbH (PROGEN), Heidelberg, into november AG i.I. by the company Biomed Beteiligungsgesellschaft mbH and Mr. Dr. Claus Müller. The contribution of both companies will presumably - among other conditions - be subject to a final, legally binding resolution of the shareholder’s meeting on the said corporate action, the exemption from the obligation to publish and make a mandatory offer by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) according to § 37 Takeover Act (WpÜG) and the successful termination of the insolvency proceedings on the assets of november AG. For this purpose, it is intended to enter into a contribution contract with Biomed Beteiligungsgesellschaft mbH and Mr. Dr. Claus Müller prior to the shareholder’s meeting. For purposes of the capital increase against contribution in kind with the exclusion of the shareholders’ subscription rights and in consideration of the capital reduction, 10,287,356 new notional non-par-value shares shall be issued at an issue price of Euro 1.74 per notional non-par-value share (arithmetically Euro 0.87 per share prior to the capital reduction). Moreover, the shareholder’s meeting shall in consideration of the capital reduction and the capital increase against contribution in kind decide on a capital increase for cash by up to Euro 7,020,758.00 with subscription rights for the shareholders. end of announcement euro adhoc 04.04.2007 13:59:35 -------------------------------------------------------------------------------- ots Originaltext: november AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Marcus Weichert Leitung PR/IR Telefon: +49(0)9131 75088 868 E-Mail: weichert@november.de Branche: Biotechnology ISIN: DE0006762909 WKN: 676290 Index: CDAX, Technologie All Share, Prime All Share Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime standard Börse Berlin-Bremen / free trade Baden-Württembergische Wertpapierbörse / free trade Börse Düsseldorf / free trade Niedersächsische Börse zu Hannover / free trade Bayerische Börse / free trade

Das könnte Sie auch interessieren: